A New Generation of Potent Adjuvants

Schepens Eye Research Institute
posted on 03/04/2009

Adjuvants such as alum are used in vaccination to promote the immune response. The bacterial-based adjuvants augment antigen-presenting cell activity to enhance the immunogenicity of the vaccine, but such adjuvants cause severe inflammatory reactions. Specific neuropeptides found in the eye modulate innate and adaptive immunity and can be used to promote immunity associated with vaccination and to minimize the side-effects of immunization. The combination of a neuropeptide with an immunogen modifies the immune response to the immunogen according to the specific need: induction or suppression of vaccine induced inflammation or specific cellular immunity. The technology finds applications in vaccination, immunotherapy and in the development of treatments against autoimmune diseases.

Innovation Details

File Number: SERI-145 

Other Information:

Ph.D. Andrew Taylor

Mary Chatterton, Director of Corporate Alliances.

IP Protection

License Online

This innovation currently is not available for online licensing. Please contact the case manager at Schepens Eye Research Institute for more information.

Request more info via email request more info

No people are currently associated with this innovation.

Download Technology Brief (PDF)

Followed By

Follow this innovation

No one is following this innovation.

Related Tags

Find more innovations

February 11, 2009

13,277 members 17,569 innovations 176 organizations


Scott Steele, coordinator of the CTSA-IP initiative and director of research alliances at the University of Rochester

"With more than 3,700 innovations from CTSA member institutions already on the iBridge Network, we're garnering worldwide exposure for the breakthroughs our researchers are accomplishing while moving toward our goal of increasing human health through clinical and translational research."  read more...